Identification of Genetic Diseases Using Breast Milk Cell Analysis: The Case of Transient Neonatal Zinc Deficiency (TNZD)

Abstract
Infants exclusively breastfed with zinc-deficient milk, develop transient neonatal zinc deficiency (TNZD) due to inactivating mutations in the maternal zinc transporter SLC30A2/ZnT2. In the current study, DNA sequencing of the SLC30A2/ZnT2 gene in a mother exclusively breastfeeding her infant which presented with TNZD symptoms, identified a single nucleotide missense mutation c.839G>T. This mutation was initially predicted to result in a single amino acid substitution p.(Gly280Val). However, c.838G was also predicted to be located close to a 3’-splice site. Hence, using sequencing of mRNA isolated from the mother’s breast milk cells, we discovered that the c.839G>T mutation creates an alternative 3’-splice site, introducing a 27 bp exon skipping. The resultant mutant protein lacking 9 amino acids (Δ9AA) failed to dimerize with the wild type (WT) ZnT2 protein and displayed enhanced degradation. Furthermore, the zinc transport ability of this ZnT2 protein was completely lost as shown by intracellular zinc accumulation using the zinc fluorescent probes Zinquin and Fluozin 3 AM. These findings reveal that the Δ9AA-ZnT2 variant did not exert a dominant negative effect over the WT ZnT2 protein. Hence, we provide direct evidence that a haploinsufficiency state occurs in women with heterozygous SLC30A2/ZnT2 mutations. Importantly, we herein developed a novel genetic test of expressed genes using maternal breast milk cells, which is well suited for the early diagnosis and prevention of TNZD and possibly other micronutrient deficiencies.

Key words: Zinc transporter; Neonatal zinc deficiency; Breast milk; Early diagnosis; Haploinsufficiency

Introduction
Cumulative evidence indicates that some exclusively breastfed infants suffer from severe zinc deficiency due to lack of zinc in the breast milk they consume [1-8]. The main initial symptoms of zinc deficiency are dermatitis, diarrhea, alopecia, and loss of appetite[9]. However, some cases of zinc deficiency are misdiagnosed and infants are treated with drugs against eczema or impetigo. Infants are particularly vulnerable to zinc deficiency as they require large amount of zinc for their normal growth and development. In this respect, preterm infants are born with low hepatic zinc stores and display a low intestinal zinc absorption capacity[10] hence, they are more prone to develop zinc deficiency in the first months of life [11].

Two distinct genetic disorders can cause zinc deficiency in infants. Acrodermatitis Enteropathica (AEZ; OMIM #201100) is an autosomal recessive disease [12,13] which presents after weaning. Acrodermatitis Enteropathica is a result of loss of function mutations in the zinc transporter Zip4 (SLC39A4), which leads to impaired intestinal absorption of zinc [14]. Hence, infants harboring Acrodermatitis Enteropathica must receive zinc supplementation for their whole life. In contrast, transient neonatal zinc deficiency (TNZD; OMIM #608118) appears only in exclusively breastfed infants as a result of low zinc concentration in the breast milk of their nursing mothers [9]. Thus, infants harboring TNZD have no zinc absorption impairment and are completely cured after zinc supplementation of their breast milk and after weaning. TNZD is predominantly a result of loss
of function mutations in the SLC30A2 gene [1,3–5, 7, 8, 15]. SLC30A2 encodes for the zinc transporter ZnT2 which is responsible for zinc accumulation in intracellular vesicles, in lactating mammary epithelial gland cells. Through exocytosis, these zinc-loaded vesicles secrete zinc into breast milk [16]. Excluding one case of compound ZnT2 mutations [4], and two cases with no detectable mutations in the coding region of SLC30A2 (although the promoter region was not sequenced) [17, 18], all TNZD cases reported to date were found in mothers harboring heterozygous loss of function mutations in SLC30A2.

Zinc concentrations in breast milk vary largely within and between mothers at different stages of lactation [19]. As a result, it is difficult to determine the reference levels of zinc concentration in human breast milk [19]. However, it appears that in cases of TNZD, zinc levels in breast milk are much lower compared to control breast milk determinations from the first days of lactation [2]. Taking into consideration the large variability in zinc concentrations in breast milk, and the fact that there is no gold standard method and an established clinical protocol for reliable quantification of zinc concentration in breast milk, it remains highly essential to develop a reliable, easy, rapid, and non-invasive tool for early diagnosis of TNZD.

Towards this end, we herein report on the development of a novel genetic approach for the early diagnosis of ZnT2 mutations associated with TNZD using genetic analysis of mRNA isolated from breast milk cells. Specifically, we identified and characterized a novel ZnT2 mutant protein which results from impaired splicing with consequently decreased ZnT2 protein stability as well as disruption of ZnT2 homodimerization. It should be emphasized that this impaired splicing could not be predicted from the genomic single nucleotide mutation in the SLC30A2 gene. This TNZD case is the first step towards the early genetic diagnosis of other genetic disorders which are associated with proteins that are expressed in mammary gland epithelial cells.

**Materials and Methods**

**Chemicals and Reagents:** The DNA dye Hoechst 33342 was purchased from Sigma-Aldrich. The cell permeant, viable fluorescent zinc probe Zinquin ethyl ester was obtained from Biotum (Hayward, CA), whereas Fluozin3-AM was from Thermo Fisher Scientific. Zinc sulfate was obtained from Merck.

**Determination of zinc concentration in breast milk:** Fresh human milk samples were collected from mothers and were stored at -20°C until analysis. Zinc quantification was performed using electrothermal atomic absorption spectrometry as described previously [20]. Each sample was quantified in duplicates on two different days. The current study was approved by the Institutional Review Board of the RB Rappaport Faculty of Medicine (US-HHS-FWA-00013345, 20-2016). Written consent was obtained from all subjects. Blood samples were derived from two women with matched infant ages (7 months old). Diagnostic primers were designed to detect the two different alleles i.e. the WT and the truncated Δ9AA variant. The first primer pair was designed to detect only the WT-ZnT2 transcript as the forward primer targeted the 21 bp that were deleted from the mRNA of the Δ9AA variant (Figure 2A, 844-F). In contrast, the second forward primer was designed to detect only the deleted mRNA and hybridized solely to the mRNA that lacks the 27 bp (Figure 2A-Δ9AA-4mm-F). For this purpose, we designed a forward primer which contains 19 bp that hybridized with the sequence upstream to the deleted segment, and 2 bp following the deletion (Figure 2A- Δ9AA-4mm-F). In addition, for better specification, we added a mismatch in the fourth nucleotide at the 3’ of the forward primer c.837A>T (Figure 2A- Δ9AA-4mm-F) [22]. Real-time PCR was performed using an Applied Biosystems-Life Technologies 7300 Real-Time PCR. A quantitative PCR reaction (20μl) contained 5ng of cDNA. PerfeCTa SYBR Green FastMix reagent was used (Quantabio, MA, USA). The primers used for allele quantification are listed in Table 2. We first performed a real-time PCR on known template amounts and compared the threshold cycle (Ct) values obtained with each primer; we found no difference between the efficacies of the two primers. For each sample we performed a triplicate quantification and then calculated the mean Ct. DNA quantification values for each primer pair in each sample were calculated using the parameters of the standard curve (b: intercept; a: slope) as follows: value=10[(b–a)/Ct] [23]. For each sample, we calculated the percentage of relative expression of each allele from the total expression (total expression was the sum of the two allele values).

**Expression vector construction:** Bimolecular fluorescence complementation (BiFC) constructs of ZnT2 were generated as
Table 1 Actual impact of a single nucleotide substitution on the ZnT2 protein.

<table>
<thead>
<tr>
<th>Nucleotide substitution</th>
<th>Predicted amino acids substitution</th>
<th>Actual impact on the ZnT2 protein</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>c.839G &gt; T</td>
<td>p.Gly280Val</td>
<td>Exon skipping of 27 bp, caused a deletion of 9 amino acids. Gly280 was substituted by Alanine and the following 8 amino acids (p.Thr281_Ala289) were deleted.</td>
<td>Current paper</td>
</tr>
</tbody>
</table>

Figure 1 Impact of a single nucleotide mutation at the DNA level on the RNA and protein sequence.
A) Pedigree showing the family relations between the patients. B) Facial rash of II:2 at the age of 13 weeks. C) SLC30A2/ZnT2 DNA sequence of mother I:1. The point mutation is marked by an arrow. D) SLC30A2/ZnT2 mRNA sequence of mother I:1. The arrow indicates the beginning of the double sequence (i.e. WT and mutant), as a result of the deletion. We observed the same findings upon DNA and RNA sequencing in mother I:2 (data not shown). E) Amino acid sequence showing the region of the 9 amino acid truncation (Δ9AA).
### Table 2: Primers used for PCR.

<table>
<thead>
<tr>
<th>Purpose</th>
<th>Name</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td>Site-directed mutagenesis recapitulating the deletion of 27 bp of ZnT2</td>
<td>ZnT2-del-839-865</td>
<td>GGTGTGTAGGAACGTGAGATC</td>
<td>GCCATACGAACACTCCATCAACACC</td>
</tr>
<tr>
<td>ZnT2 mRNA sequencing</td>
<td>ORF1-ZnT2</td>
<td>ACTGCGATGAGGCCAAGGAG</td>
<td>GTGGCGATCACTGGATG</td>
</tr>
<tr>
<td>ZnT2 mRNA sequencing</td>
<td>ORF2-ZnT2</td>
<td>CTGCGTACCTCGCTGAGGAG</td>
<td>TGAGCATCGTGCTGAGGGGC</td>
</tr>
<tr>
<td>Real-time</td>
<td>Δ9AA-4mm-ZnT2</td>
<td>GATCGTGTGATGGAAGCTGTTCGTGATCTGC</td>
<td>TGAGCATCGTGCTGAGGGGC</td>
</tr>
<tr>
<td>Real-time</td>
<td>WT-ZnT2</td>
<td>CCAAGGGGCGTTGACTTCCA</td>
<td>GATGGGACAGACAAGAGCCTGG</td>
</tr>
</tbody>
</table>

### Figure 2: Allele quantification using real-time PCR analysis.

A) Schematic illustration of the difference between WT-ZnT2 and Δ9AA-ZnT2 mRNAs. Arrows represent the location of the real-time PCR primers. 4 mm represents the fourth nucleotide mismatch c.837A>T (red colored) for better specification of the primer. Nucleotide numbering is based on the CDS of SLC30A2/ZnT2 mRNA variant 1 (NM_001004434.2). “F” indicates forward primer, whereas “R” indicates reverse primer.

B) Percent of specific ZnT2 allele (WT-ZnT2 or Δ9AA-ZnT2) expression of total ZnT2 mRNA expression (WT-ZnT2 + Δ9AA-ZnT2). Control 1 and 2 represent healthy individuals. Asterisks denote that the values below obtained were statistically significant when compared to the values with control 1 (p<0.05). Real-time PCR quantification was performed 3 independent times and mean values are presented. Error bars represent S.D.
previously described [24]. The 27 bp deletion was introduced into the ZnT2 expression plasmids using Pfu Turbo DNA polymerase (QuikChange kit, Stratagene, La Jolla, CA) and primers listed in Table 2. The coding region of the Ruby tag was amplified using mRuby-Lifeact-7 expression vector and the primers Xho-pmRuby-F 5’ATACTCGGACCATGAACACGCTGTACAAA 3’ and mRuby- Xba-R 5’ ATATCGATTACCTGCCGCCCAGCCG 3’. The PCR products were then sequenced to verify that they contained the correct length of the insert using agarose gel electrophoresis, following which the DNA was purified from the gel using a Promega Wizard SV gel & PCR cleanup system. The purified PCR products were digested with the appropriate restriction enzymes and were cloned into the pcDNA3.1-Zeo-ZnT2-containing constructs in a vector: insert ratio of 1:6 using the same restriction enzymes. The ligation was performed for 30 min at room temperature and the ligation products were transformed into heat shock competent E. coli DH5α. Positive colonies were selected using PCR. The fidelity of the insert and the tag were confirmed by direct sequencing (Hy-labs, Israel).

**BIFC terminology:** YN and YC represent the non-fluorescent N- and C-terminal halves of YFP, respectively. Transfection with the construct-YN-YC-YN implies that plasmids containing the construct-YN and the construct-YC were co-transfected into cells. Construct-YFP indicates that plasmids encoding for the full-length YFP fluorescent protein were transfected.

**Cell culture, transient transfections, Flow cytometry and confocal laser microscopy:** MCF-7 breast cancer cells were grown and transiently transfected as previously described [3,24]. Twenty-four hrs after transfection, cells were stained with Zinquin ethyl ester (40 µM) or Fluozin3-AM (1µM) and were analyzed using flow cytometry or confocal microscopy, respectively. For the zinc transport experiments, cells were incubated for 2 hrs with growth medium containing 75 µM ZnSO₄ before staining. Cells were then rinsed with PBS and incubated in growth medium containing 40 µM Zinquin ethyl ester and were analyzed with a flow cytometer as previously described [3,25]. For confocal microscopy, cells were incubated in growth medium containing 1µM Fluozin3-AM for 30 min, following which they were washed 3 times with PBS. Cells were then incubated for another 30 min in growth medium at 37°C to allow a complete de-esterification of intracellular AM esters. Finally, cells were washed with PBS and then incubated in PBS containing 1 mM MgCl₂, 1 mM CaCl₂ and 10 mM D-glucose at pH 7.4. Hoechst 33342 (2 µg/ml) was used for viable nuclear DNA staining. Live cells were imaged using an inverted confocal microscope (Zeiss LSM 710) at a magnification of X63 under immersion oil.

**Assessment of ZnT2 dimerization in BiFC transfectants using Western blot analysis:** MCF-7 cells were transiently transfected with the designated plasmids (3 µg in single construct transfection and 1.5 µg DNA of each construct in co-transfections). Membrane proteins were isolated on ice using an extraction buffer as previously described [25]. Briefly, proteins (30 µg) were resolved by electrophoresis on 10% polyacrylamide gels, electroblotted onto cellulose nitrate membranes, blocked with Tris-buffered saline (TBS)-milk and reacted with mouse anti-ZnT2 monoclonal antibody (at 1: 2,000 dilution, 1 hr in room temperature; generously provided by Prof. T. Kambe, Kyoto University, Kyoto, Japan). Blots were then washed three times with TBS for 10 min each at room temperature and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG (1:20,000 dilution; Jackson Immunoresearch Labs, West Grove, PA; catalog number: 115035062) for 1 hr at room temperature. After three washes, enhanced chemiluminescence detection was performed according to the manufacturer’s instructions (Biological Industries, Beth-Haemek, Israel). Similarly, actual protein loading onto the SDS-PAGE gels was confirmed by blot reprobing with a rabbit polyclonal antibody against the α subunit of Na⁺/K⁺ ATPase (KETTY at 1: 3,000 dilution; kindly provided by Prof. S.J.D. Karlish, Weizmann Institute of Science, Rehovot, Israel) and detected with horseradish peroxidase-conjugated goat anti-rabbit IgG (1: 15,000 dilution; Jackson Immuno-Research Labs, West Grove, PA; catalog number: 115035045).

**Detection of native human ZnT2:** Breast milk (30 ml) was centrifuged at 2,000xg for 5 min at 4°C and was separated into 3 fractions (fat layer, skim milk and cells fraction). Membrane protein extraction buffer (100 µl) [24] was added directly to the fraction of cells (bottom fraction). Samples were then incubated on ice for 30 min and centrifuged at 20,000xg for 15 min at 4°C. The fraction containing membrane proteins was collected and proteins (20 µg) were resolved by electrophoresis on 10% polyacrylamide gels as described above. Mouse anti-ZnT2 monoclonal antibody was used for Western blot analysis (at 1:3,000 dilution, 1 hr in room temperature). Actual protein loading onto the SDS-PAGE gels was confirmed by blot reprobing with a rabbit polyclonal antibody against actin (at 1:1,000 dilution, overnight at 4°C; Sigma-Aldrich; catalog number: A2066).

**Evaluation of the half-life of WT and mutant ZnT2 using cycloheximide inhibition of translation:** MCF-7 cells were seeded and transiently transfected as described above. Sixteen hrs after transfection, the growth medium was replaced by fresh medium containing 50 µg/ml cycloheximide (CHX). Membrane proteins were isolated every 0.5-1 hr using an extraction buffer and Western blot analysis was performed as described above.

**Quantification of protein after Western blot analysis:** Western blot analysis was performed using Quantity One® 1-D analysis software, by Bio-Rad Laboratories, Inc.

**Statistical analysis:** Results are presented as means ± S.D. Statistical comparisons were performed using two tailed Student’s t test (Prism Graph Pad, Berkeley, CA), and a significant difference was demonstrated when p value was < 0.05. Results from at least three independent experiments are shown.

**Results**

**Clinical data and early genetic diagnosis of TNZD:** Preterm infant (II:2 in Figure 1A) suffered from a severe erythematous scaly rash involving his face, neck, diaper area at the age of 13 weeks (Figure 1 B). The rash was first diagnosed as calcificant seborrheic dermatitis with possible secondary impetigo. Therefore, the infant was treated with different ointments
including topical antibiotics and steroids without improvement. After 3 weeks with worsening in the skin findings, physicians considered the possibility of zinc deficiency. Indeed, the infant’s plasma zinc levels were extremely low (4.5 µg/dL; normal range 55-165 µg/dL). Zinc supplementation (5 mg/day) was initiated and within 4-5 days of supplementation, the infant’s appetite improved, weight gain was restored and the skin rash has completely vanished in 2 weeks.

We hence introduced here a new genetic screening technique based on sequencing of ZnT2 mRNA isolated from breast milk cells; we specifically sequenced the ZnT2 mRNA of Mother 1 (I:1 in Figure 1 A) and her sister, Mother 2 (II:2 in Figure 1 A) that also gave birth, and had a 4 months old baby girl without any symptoms of zinc deficiency. After identifying the very same alternative 3’-splice ZnT2 variant in mRNA extracted from their breast milk cells, we offered Mother I:2 to determine zinc blood levels in her exclusively breastfed daughter (II:3 in Figure 1 A). Indeed, her daughter (II:3 in Figure 1 A) displayed a mild zinc deficiency (41 µg/dL, normal range 55-165 µg/dL). Thus, the present study constitutes the very first case of an early diagnosis of TNZD reported to date. It is important to emphasize that II:1 of TNZD was also exclusively breastfed; however, mother I:1 did not notice any unusual symptoms in her daughter, probably because she had only a mild zinc deficiency which was not associated with apparent symptoms, just like her cousin (II:3 in Figure 1 A), that was completely cured after weaning. Breast milk zinc concentrations were 6 and 11 µg/dL for I:1 and I:2, respectively (normal median range 85 µg/dL at 7 months of lactation, minimum level 44 µg/dL and maximum level 136 µg/dL).[19].

DNA and RNA sequencing: DNA sequencing of I:1 and I:2 identified a single nucleotide shift resulting in a synonymous mutation c.546G>A (Nucleotide number 1 refers to the first nucleotide of the ATG codon of the long ZnT2 mRNA variant NM_0010044343.2) which does not alter the protein sequence (p. Ser182=). Furthermore, this genomic DNA sequencing identified a single nucleotide missense mutation c.839G>T (Figure 1 C). This missense mutation was initially predicted to result in a single amino acid substitution p.(Gly280Val) (Table 1). However, c.838G in ZnT2 was recently predicted to be located close to 3’ splice site [5]. Therefore, we undertook further experiments to explore the impact of this genomic c.839G>T mutation on the splicing of ZnT2 pre-mRNA. Indeed, sequencing of mRNA isolated from breast milk cells revealed that the missense genomic mutation c.839G>T results in an alternative 3’ splicing, culminating in an exon skipping of 27 bp (c.839_865del). As shown in Figure 1D, starting with nucleotide c.839G, mRNA sequence analysis revealed two distinct mRNAs: a WT mRNA and a 27 bp truncated allele (Δ9AA -YN+Δ9AA-YC). The YFP fluorescence that we observed in living cells [3, 24, 25] . High YFP fluorescence intensity indicates the ability of the alternative 3’ splice variant (Δ9AA) to disrupt ZnT2 homodimerization: we first evaluated the ability of the alternative 3’ splice variant (Δ9AA) ZnT2 to form homodimers using the BicF assay that we have previously applied for the detection of in situ dimerization of ZnT2 and other ZnTs in living cells [3, 24, 25]. High YFP fluorescence intensity indicates a strong interaction between the two tagged proteins, which enables the refolding of the two non-fluorescent halves of YFP (YN and YC) into a fully fluorescent protein. As determined by flow cytometry (Figure 4A), we found that the alternative 3’ splice ZnT2 variant which lacks 9 amino acids in the C-terminus, lost the ability to form homodimers (Figure 4A, Δ9AA -YN+Δ9AA-YC). We further found that Δ9AA -ZnT2 failed to form homodimers with the native WT-ZnT2 (Figure 4A, ZnT2-YN+ Δ9AA -YC and Δ9AA -YN+ZnT2-YC). The YFP fluorescence that we observed in all transfections with the truncated Δ9AA -ZnT2 construct was at the background level found with the negative control of the WT and the Δ9AA variant alleles are expressed and highlight the importance of performing a gene expression screen at the mRNA level upon identification of a genomic SLC30A2/ZnT2 mutation.

Development of diagnostic primers for the detection of both the 27 bp truncated allele and the WT allele: We next assessed whether or not the WT and truncated alleles are equally distributed in order to understand the molecular mechanism underlying the presumed haploinsufficiency state that we have recently proposed in TNZD [3]. To quantify the distribution of the WT and the truncated ZnT2 mRNA alleles, we designed diagnostic primers. The first set of primers was designed to detect solely the WT-ZnT2 allele (Figure 2A). In contrast, the second forward primer was selected to detect only the truncated ZnT2 mRNA (Δ9AA), hence hybridizing solely to the mRNA lacking the 27 bp (Figure 2A and Materials and Methods). We found that while both healthy individuals (Control 1,2 Figure 2B) expressed only the WT-ZnT2 allele, the two mothers harboring TNZD-associated mutations, expressed between 40-60% of the WT allele and the remaining transcript represented the truncated Δ9AA allele (Mother I:1,2 Figure 2B). These results demonstrate that the two alleles were comparably expressed in both mother I:1 and mother I:2.

Native human ZnT2 variant (40 kDa) expressed in breast milk cells: To verify the expression of the WT ZnT2 protein in women with zinc-deficient breast milk, we extracted membrane proteins from the breast milk cell fraction; we found that both mother 2 and control 1 expressed predominantly the 40 kDa variant of the WT ZnT2 (Figure 3). However, taking into consideration the slight differences in the actin protein levels, one can suggest that mother 2 expressed less ZnT2 protein compared to control 1. The 9-amino acid deletion in the ZnT2 protein could not be detected on SDS-PAGE, and we therefore could not determine whether the Δ9AA variant protein was expressed. However, these findings lend further support to our suggestion that a haploinsufficiency state occurs for the unaffected WT allele in producing zinc-deficient breast milk. Although mother 2 had sufficient levels of the ZnT2 protein, her breast milk was zinc-deficient and led to a mild zinc deficiency in her infant.

The alternative 3’ splice variant (Δ9AA) associated with TNZD, disrupts ZnT2 homodimerization: We first evaluated the ability of the alternative 3’ splice variant (Δ9AA) ZnT2 to form homodimers using the BicF assay that we have previously applied for the detection of in situ dimerization of ZnT2 and other ZnTs in living cells [3, 24, 25]. High YFP fluorescence intensity indicates a strong interaction between the two tagged proteins, which enables the refolding of the two non-fluorescent halves of YFP (YN and YC) into a fully fluorescent protein. As determined by flow cytometry (Figure 4A), we found that the alternative 3’ splice ZnT2 variant which lacks 9 amino acids in the C-terminus, lost the ability to form homodimers (Figure 4A, Δ9AA -YN+Δ9AA-YC). We further found that Δ9AA -ZnT2 failed to form homodimers with the native WT-ZnT2 (Figure 4A, ZnT2-YN+ Δ9AA -YC and Δ9AA -YN+ZnT2-YC). The YFP fluorescence that we observed in all transfections with the truncated Δ9AA -ZnT2 construct was at the background level found with the negative control of the
WT-ZnT2-YN+β2AR-YC co-transfection. Upon transfection of the Δ9AA-YFP construct we observed relatively prominent levels of YFP fluorescence which confirmed the expression of the Δ9AA-ZnT2 protein. However, the YFP fluorescence levels of the Δ9AA-YFP protein were lower when compared to WT-ZnT2-YFP levels, indicating that the deletion of this 9-amino acid segment at the C-terminus possibly decreases the expression and/or stability of this truncated ZnT2 protein. This hypothesis was first evaluated using confocal laser microscopy (Figure 4B). Indeed, YFP fluorescence was neither detected upon co-transfection with the Δ9AA-YN+Δ9AA-YC constructs nor upon co-transfection with Δ9AA-YC+ZnT2-YN, or with the Δ9AA-YN+ZnT2-YC constructs (Figure 4B). These findings indicate that the truncated Δ9AA-ZnT2 protein has lost its homodimerization capacity. These results further show that the truncated Δ9AA-ZnT2 protein cannot exert a dominant negative effect over the WT-ZnT2 protein as it cannot form dimers.

Δ9AA-ZnT2 protein undergoes enhanced degradation: As the above flow cytometry results with the YFP tag suggested enhanced degradation of the Δ9AA-ZnT2 protein, we first undertook experiments to explore its ability to form homodimers. As we previously showed [25], upon dimerization of WT ZnT2-YN+ZnT2-YC, the BiFC tags refold and tightly interact as a result of the formation of multiple hydrogen bonds, thereby forming dimers that are metastable in SDS-PAGE (Figure 5A). Upon transfection with Δ9AA-YN or Δ9AA-YC constructs, we observed lower ZnT2 levels, compared to transfection with the WT-ZnT2 as revealed by Western blot analysis (Figure 5A). However, in contrast to the WT protein which was predominantly present in the homodimer form (Figure 5A, upper band), upon co-transfection with Δ9AA-YN+Δ9AA-YC, no homodimers were detected (Figure 5A). Furthermore, upon co-transfection of ZnT2-YN along with Δ9AA-YC, the protein levels were substantial, yet no homodimers were detectable (Figure 5A, right side). These results indicate that the lower expression levels or increased degradation of the truncated Δ9AA ZnT2 protein were not the only causes for the loss of the dimerization capacity. These findings suggest that the deleted C-terminal region of ZnT2 has a major role in protein-protein interactions and dimer formation.

We next determined the protein levels of WT-ZnT2-YFP compared to the truncated Δ9AA-ZnT2-YFP (Figure 5B) after transient transfection and Western blot analysis. We found that 24 hrs after transfection, the Δ9AA-ZnT2 protein was expressed at a level that was ~25% that of the WT protein (Figure 5B). Thus, in order to determine the molecular basis underlying this decreased levels of the Δ9AA-ZnT2 protein, we directly determined the half-
lives of the truncated Δ9AA-ZnT2 and the WT ZnT2 proteins using the cycloheximide (CHX) treatment method [4]. As shown in Figure 5B, we found that the levels of the truncated Δ9AA-ZnT2 protein were significantly lower at $t_0$ compared to the WT ZnT2 protein, and more importantly, the degradation rate of the Δ9AA-ZnT2 protein was significantly enhanced when compared to that of the WT ZnT2 protein (Figure 5C). Quantification of the ZnT2 bands upon Western blot analysis revealed that the half-life ($t_{1/2}$) of the WT-ZnT2-YFP protein was ≈ 4.5 hrs, whereas that of the truncated Δ9AA-ZnT2-YFP protein was only ≈2 hrs (Figure 5D). These results provide direct evidence for the enhanced degradation of the Δ9AA-ZnT2 protein, hence providing the molecular basis for the low expression levels observed with the truncated Δ9AA-ZnT2 protein, when compared to the WT-ZnT2 protein.

The alternative 3’ splice variant Δ9AA ZnT2 is devoid of a zinc transport function: In order to determine whether or not the
Figure 5  **The Δ9AA-ZnT2 protein undergoes fast degradation.** MCF-7 cells were transiently co-transfected with the constructs described above. Western blot analysis was performed after SDS-PAGE under denaturing conditions using an anti-ZnT2 antibody (Upper panel), or anti α-subunit of Na+/K+ ATPase to confirm equal protein loading (lower panel). A) Different expression levels using the various constructs and the ability of WT-ZnT2 to form homodimers that was lost in the truncated Δ9AA protein. B) Bands from 3 independent experiments were quantified in order to compare the actual expression levels of the different proteins (WT-ZnT2 and Δ9AA-ZnT2). C) Western blot analysis after cycloheximide (CHX) treatment. D) Quantification of the Western blot band, specifically showing the half-life (t½) of WT-ZnT2-YFP and Δ9AA-ZnT2-YFP proteins. Asterisks 28 represent statistically significant differences (p<0.05) from WT-ZnT2-YFP at the same time point. Error bars represent S.D.

truncated Δ9AA ZnT2 protein retained zinc transport activity, we used two distinct viable fluorescent zinc probes, Fluozin-3 AM and Zinquin ethyl-ester. MCF-7 cells transfected with the tagged WT-ZnT2-Ruby exhibited a high number of fluorescent intracellular vesicles upon staining with Fluozin-3, a cell-permanent fluorescent zinc indicator. This confirmed the key role that the WT ZnT2 plays in compartmentalization of zinc in intracellular vesicles. In contrast, upon transfection with the truncated Δ9AA-Ruby, we observed low levels of red fluorescence, consistent with the fast degradation of the Δ9AA-Ruby protein (as shown in Figure 6A), and we also observed a very low number of intracellular zinc-containing vesicles (Figure 6A); this background number of Fluozin-3-stained vesicles in the Δ9AA-Ruby transfected cells was similar to that observed upon transfection with the RFP-Empty vector (Figure 6A). The second fluorescent zinc probe that we used was Zinquin ethyl-ester which we and others previously employed in order to follow zinc accumulation in intracellular vesicles [24, 25]. We show here that in contrast to the zinc transport activity of WT-ZnT2-YFP and WT-ZnT2-YC-YN, the truncated Δ9AA-YFP protein failed to mediate the accumulation of zinc in intracellular vesicles. We therefore obtained low levels of Zinquin fluorescence that were similar to the background levels observed upon transfection with the YFP empty vector (which did not contain a ZnT2 insert) or to the dominant negative p.Gly87Arg ZnT2 mutant that we previously showed to be devoid of zinc transport activity (Figure 6B). These results indicate that the Δ9AA-ZnT2 variant lost the ability to transport zinc into intracellular vesicles.

**Discussion**

Extraction of RNA from breast milk was recently shown to be a rapid, facile, and non-invasive technique for studying the gene expression profile in mammary gland epithelial cells. For example, J. Sharp and his colleagues reported on the differences in the transcriptomics profiles at the various stages of lactation [23]. Furthermore, C. Cai and his group studied the role of the gene expression profile of mammary gland epithelial cells isolated from breast milk in the iron uptake pathway [26]. Hence, we herein developed a novel genetic tool for the identification of distinct ZnT2 mutations and genetic variants using cells isolated...
from breast milk at the expressed mRNA level. This genetic analysis can serve as a reliable screening platform for the early diagnosis of TNZD and can prevent zinc deficiency in infants before the severe symptoms appear. In the case of TNZD, the early diagnosis using breast milk cells is critical because of the following reasons: 1) The diagnosis of mild zinc deficiency is very complex, and most cases remain undiagnosed or misdiagnosed until the severe symptoms emerge. In addition, the blood test of zinc levels is not properly reflecting the exact body zinc status, at the middle ranges i.e. between normal levels and severe deficiency [27]. 2) Infants at the age of one month to one year are not tested routinely for blood micronutrient levels, unless they have health problems. 3) Upon early diagnosis of TNZD, the infant can be easily supplemented with zinc and can continue breastfeeding without any pathological symptoms.

We showed here for the first time, that single nucleotide mutations at the genomic DNA level in the ZnT2 gene may result in completely distinct deleterious alterations at the mRNA and amino acids levels which could not be simply predicted from the genomic mutation identified. In this respect, alterations at the genomic DNA level in a given genetic disease may predict a certain impact on the protein level which may be completely erroneous and misleading. In contrast, at the expressed mRNA level, the deleterious impact of the mutation will be most accurate and fully representative. Consistently, we herein successfully detected this unique ZnT2 splice variant only when using cells isolated from breast milk as ZnT2 is not ubiquitously expressed in different tissues.

We previously suggested a haploinsufficiency state for the unaffected WT ZnT2 allele in TNZD pathology [3]. This suggestion was based on three different heterozygous mutations that caused TNZD without exerting a dominant negative effect over the WT ZnT2 protein [3, 5]. In the current paper, we provide direct support for this hypothesis as shown in the TNZD case we characterized here. Specifically, while the WT transcript was nearly equally expressed as the mutant allele (Figure 2), and there was sufficient native expression of the ZnT2 protein
(Figure 3), the truncated Δ9AA-ZnT2 protein failed to form homodimers with the WT-ZnT2 protein (Figure 4). This was true in spite of the fact that the actual cellular WT-ZnT2 protein levels were significantly higher than those of the Δ9AA-ZnT2 protein (Figure 5). Hence, these high levels of the WT-ZnT2 protein were not sufficient to mediate adequate zinc transport to meet the infant’s requirements (Figure 1, II:2). We further suggest that production of zinc-deficient milk leading to TNZD is an autosomal dominant disease which exhibits incomplete penetrance. Other factors that may affect the appearance of TNZD in the infant are gestational age at birth, birth weight, intrinsic liver zinc stores at birth [28], milk formula consumption and more. It is important to note that Son1 was born as a premature infant, as it is well known that premature infants are prone to zinc deficiency because of their meager hepatic zinc stores and their low intestinal zinc absorption capacity [11]. However, most premature infants that consume breast milk containing adequate zinc concentrations will not develop severe zinc deficiency. In addition, daughter 2 which was born in term (after 40 weeks of gestation), was found to harbor a mild zinc deficiency at the age of 4 months without any serious symptoms. This infant could develop a severe zinc deficiency at a later stage if she was left untreated and was continuing exclusive breastfeeding or could remain at a mild zinc deficiency state without being diagnosed. Mild zinc deficiency in children was linked to neurological and cognitive changes [29], growth retardation [30], immune deficiency and higher morbidity of diarrhea and pneumonia [27]. The nonspecific symptoms of mild zinc deficiency make it hard to diagnose and as a result, most cases remain undiagnosed and hence untreated [31]. The current study constitutes the first case of early diagnosis of zinc deficiency in an infant that was treated with zinc supplements and TNZD was prevented. Using our novel genetic screening tool with ZnT2 mRNA isolated from breast milk cells, we could easily identify a breast milk sample from mothers at the first days of lactation and prevent infant’s exclusive nursing by mothers harboring a ZnT2 mutation which inflicts the severe symptoms of TNZD. Furthermore, this novel diagnostic technique could be also applied for the early identification of other inborn genetic diseases such as riboflavin deficiency which is common in breastfed preterm infants that may be result from mutations in the ABCG2 (BCRP) transporter that is responsible for riboflavin secretion in to breast milk [34]. In addition, using this tool we could further investigate the underlying molecular mechanism of transport of other micro- and macronutrients. Importantly, one could utilize this breast milk RNA isolation platform to detect and identify mastitis for personalized treatment depending on the origin of infection being fungal or bacterial [35].

In summary, we presented here the first case of early diagnosis of TNZD and applied a non-invasive tool for the prevention of TNZD in infants which are exclusively breastfed by mothers harboring loss of function mutations in the SLC30A2/ZnT2 gene. We provide direct evidence that a haploinsufficiency state occurs in women harboring heterozygous SLC30A2/ZnT2 gene mutations, hence suggesting that production of zinc-deficient breast milk is an autosomal dominant inheritance-based phenotype. The appearance of TNZD in the nursing infant showed a partial penetrance pattern depending on other intrinsic and environmental factors. Importantly, we highlight the importance of nucleotide sequencing at the expressed mRNA level compared to genomic DNA sequencing for the accurate identification of the molecular mechanism underlying distinct genetic diseases.
References


